were also suppressed by all these antiarrhythmic drugs. 6 The antiarrhythmic drugs, clofilium and (±)-cibenzoline block glibenclamide-sensitive K+ channels in Xenopus oocytes at concentrations comparable to their therapeutic plasma levels.
Introduction
The ATP-sensitive K+ (KATP) channel was first described in mammalian myocardial cells (Noma, 1983) , and has also been observed in the pancreatic P-cell (Ashcroft et al., 1984; Cook & Hales, 1984) , the smooth muscle (Noack et al., 1992) , the skeletal muscle (Spruce et al., 1985) and the brain (Ashford et al., 1988) . This K+ channel is activated in the presence of ATP by a new class of K+ channel openers such as cromakalim, pinacidil or diazoxide (Escande et al., 1988) , and is inactivated by sulphonylureas such as glibenclamide (Sturgess et al., 1985) , by imidazoline derivatives such as phentolamine (Plant & Henquin, 1990; Dunne, 1991) , by barbiturates such as pentobarbitone (Kozlowski & Ashford, 1991) , by phenothiazines such as chlorpromazine (Muller et al., 1991) and by the inhibitor of Ca2" mobilization, TMB-8 (Szewczyk et al., 1992) .
The oocyte of Xenopus laevis has an endogenous K+ channel which is activated by K+ channel openers such as cromakalim and pinacidil (Honore & Lazdunski, 1991) and KRN2391 (Sakuta et al., 1992a) . Since this oocyte K+ channel is inactivated by glibenclamide (Honore & Lazdunski, 1991) but not by charybdotoxin (an inhibitor of Ca2+ -activated K+ channel) or dendrotoxin (an inhibitor of voltage-dependent K+ channel) (Honore & Lazdunski, 1991) , the K+ channel appears to belong to the family of ATPsensitive K+ channels, though its sensitivity to ATP is not yet proven by single channel studies.
An agent which acts to suppress the ATP/glibenclamidesensitive K+ channel has potential as an antiarrhythmic drug (Kantor et al., 1990; Notsu et al., 1992) . Among conventional antiarrhythmic drugs, some, such as quinidine and verapamil, do suppress ATP/glibenclamide-sensitive K+ channels in rat cardiac cells (Haworth et al., 1989) . Antiar- rhythmic drugs, disopyramide, aprindine, bepridil and preAuthor for correspondence.
nylamine potently block glibenclamide-sensitive K+ channels in Xenopus oocytes with IC50 values of less than 50 JIM (Sakuta et al., 1992a) . The suppression of ATP/glibenclamide-sensitive K + channels may be involved in either favourable or unfavourable clinical effects of some antiarrhythmic drugs (see Discussion).
In the present study, we have examined the effects of five class I antiarrythmic drugs (Na+ channel blockers) and five class III antiarrhythmic drugs (agents prolonging the action potential duration (APD)) on glibenclamide-sensitive K+ channels in Xenopus oocytes. As a result, we have found that (±)-cibenzoline (a class I antiarrhythmic drug) and clofilium (a class III antiarrhythmic drug) potently suppress glibenclamide-sensitive K+ channels in Xenopus oocytes.
Methods
Voltage-clamped recording As described previously (Sakuta et al., 1992a,b) , oocytes at stage V-VI were collected from female frogs (Xenopus laevis) anaesthetized in ice, each oocyte was placed in a recording well (0.2 ml in capacity) and superfused with frog Ringer solution consisting of (in mM) NaCl 120, KCI 2, CaC12 1.8 and HEPES 5 (pH 7.4). The membrane potential of the oocyte was then voltage-clamped at a holding potential of -20 mV with two glass microelectrodes each filled with 3 M KCI (1 -2 Mohm) using the voltage-clamp amplifier, CEA-1200 (Nihon Kohden, Tokyo, Japan). This holding potential of -20 mV is close to the predicted Cl-equilibrium potential of the oocyte and was chosen to minimize the Ca2+-activated Cl-current (Honore & Lazdunski, 1991; Sakuta et al., 1992a,b) . All current responses of the oocyte were recorded at room temperature (19-23°C) with a Thermalarray Recorder, RTA-1100 (Nihon Kohden). Only follicle- Br. J. Pharmacol. (1993), 109, 866-872 . W ' ' . " Macmillan Press Ltd, 1993 enclosed oocytes (not treated with collagenase) were used for all experiments in the present study. applied to each oocyte by superfusion as described previously (Sakuta et al., 1992a) .
Application of drugs and agents

Drugs and agents used
The following drugs and agents were used (full name and source): Nakajima et al., 1992) as the concentration of Y-26763 was raised from 10 gM to 200 laM (apparent EC50 = 57.5 JM) and decreased when the concentration was increased from 500 JAM to 2 mM as shown in Figure 1 (Sakuta et al., 1992a,b) .
The Y-26763-induced current response was carried by the efflux of K+, since it was reversed at a holding potential of about -100 mV (Figure 2a) which is close to the K+ equilibrium potential of the oocyte in frog Ringer solution (Kusano et al., 1982) , and was suppressed to 55 ± 6% (mean ± s.d., n = 5) by 30 mM TEA (Figure 2b ). In five oocytes tested, Y-26763-induced K + currents were not affected either by 50 nM charybdotoxin (an inhibitor of Ca2+-activated K+ channel) or by 100 nM dendrotoxin (an inhibitor of voltage-dependent K+ channel) (Figure 2c and d).
The relatively selective inhibitor of ATP-sensitive K+ channels, glibenclamide suppressed the K+ currents induced by 50 JAM Y-26763 in a concentration-dependent fashion with an IC50 of 140 nM (Figure 3a and c (Figure 3b and c). TMB-8 is known to block not only the ATP-sensitive K+ channel in insulin-secreting cells (Szewczyk et al., 1992) but also the voltage-dependent Na+ channel and the voltagedependent Ca2+ channel (Himmel & Raven, 1990 (Sakuta et al., 1992a) . The effect of the above antiarrhythmic drugs on the KRN2391-induced current was examined. As shown in Figure 6a 
Effects of calmodulin antagonists on Y-26763 responses
Of the antiarrhythmic drugs tested in the present study, clofilium and lorcainide possess calmodulin antagonist activity (Silver et al., 1989; Mannhold et al., 1990) . Calmodulin antagonists, W-7, W-13 and W-5 (Hidaka & Tanaka, 1983) (Figure 7a-d) . This rank order of potency agrees with that of their calmodulin antagonist activities (Hidaka & Tanaka, 1983) . 
Discussion
Properties of Y-26763-induced outward currents
It is suggested that Y-26763 activates ATP-sensitive K+ channels in ventricular cardiomyocytes (Ishiguro et al., 1992) , and it was demonstrated in the present study that this K+ channel opener evokes glibenclamide-sensitive K+ currents in follicle-enclosed Xenopus oocytes (cf. Figures 2 and 3) . The Y-26763-induced K+ current was completely blocked by glibenclamide but was insensitive to both charybdotoxin and dendrotoxin (cf. Figure 2) . Therefore, Y-26763-induced K+ current may not contain either a Ca2'-activated K+ or a voltage-dependent Kt current.
TEA at a very high concentration (30 mM) suppressed Y-26763-induced currents by about 55% (cf. Figure 2) . This TEA effect is not necessarily contradictory to the property of ATP-sensitive Kt currents, because the ATP-sensitive Kt current in mouse pancreatic P-cells also shows a weak sensitivity to TEA (Bokvist et al., 1990) .
Blockade ofglibenclamide-sensitive K+ channels by antiarrhythmic drugs and possible mechanism Glibenclamide-sensitive Kt channels in Xenopus oocytes were potently blocked by clofilium and (± )-cibenzoline in the present study. We have previously reported that various antiarrhythmic drugs block the glibenclamide-sensitive K+ currents induced by KRN2391 in oocytes with potencies in terms of IC50 of 6.3 JAM for bepridil, 18 JAM for disopyramide, 30 JAM for aprindine and 38 JAM for prenylamine (Sakuta et al., 1992a). Thus, the potencies of clofilium (IC50 5.8 JAM) and ( ± )-cibenzoline (4.5 JAM) in blocking KRN2391-induced glibenclamide-sensitive K+ currents are comparable to the potency of bepridil. W-7, W-13 and W5 (calmodulin antagonists), clofilium and lorcanide blocked the K+ currents induced by Y-26763 in oocytes with the rank order of clofilium > W-7 > W-13 > W-5 > lorcainide. This rank order agreed with their reported potencies as calmodulin antagonists (potencies to inhibit Ca2+/calmodulin-dependent phosphodiesterase), that is clofilium > W-7 > W-1 3 > lorcainide > W-5 (Silver et al., 1989; Mannhold et al., 1990; Hidaka & Tanaka, 1983) . In addition, several antiarrhythmic drugs and agents having a calmodulin antagonizing activity also block the glibenclamide-sensitive K+ current induced by KRN2391 in Xenopus oocytes (Sakuta et al., 1992a) . These previous and present findings suggest that the calmodulin antagonist activity of clofilium and lorcainide contributes at least partly to their K+ channel-blocking actions.
The blocking action of KW-3407 and RS-2135 on glibenclamide-sensitive K+ currents appears to be related to phenothiazine-like aromatic rings in their structures. Phenothiazine derivatives such as trifluoperazine and chlorpromazine block ATP/glibenclamide-sensitive K+ channels (Miiller et al., 1991) . It is suggested that the calmodulin antagonizing activity of phenothiazine derivatives (Weiss & Levin, 1978) contributes to their blocking effect on ATP/ glibenclamide-sensitive K+ channels (Sakuta et al., 1992b) .
The suppressive effect of (± )-cibenzoline on glibenclamide-sensitive K+ channels in oocytes seems to be related to its imidazoline structure, since several imidazoline derivatives such as phentolamine, tolazoline and antazoline have been reported to block ATP/glibenclamide-sensitive K+ channels in insulin-secreting cells (Plant & Henquin, 1990; Dunne, 1991) . For imidazolines, however, a mechanism other than calmodulin antagonism appears to be involved in the blockade of glibenclamide-sensitive K+ channels in Xenopus oocytes, because phentolamine and tolazoline are very weak calmodulin antagonists, their IC50 values being > 500 JAM (Earl et al., 1984) .
The glibenclamide-sensitive K+ current in Xenopus oocytes is enhanced by activation of adenylate cyclase and is decreased by activation of protein kinase C (Honore & Lazdunski, 1991) . Except for clofilium, however, all drugs tested are known to affect neither the intracellular level of cyclic-AMP nor the activity of protein kinase C. Only clofilium was reported to inhibit protein kinase C, but it requires a concentration of 100 JM to do so (Silver et al., 1989) , which is about 30 times higher than its IC50 value (3.3JM) for the blockade of Y-26763-induced currents. In addition, protein kinase C inhibitors, staurosporine (1 JM) and H-7 (100IM) do not affect Y-26763-induced K+ currents (our unpublished observation). Thus, it seems unlikely that the suppressive effect of all 10 antiarrhythmic drugs tested on Y-26763-induced K+ currents is mediated by drug-induced changes in second messengers, cyclicAMP and protein kinase C.
Class I antiarrhythmic drugs, cibenzoline (Matsuoka et al., 1991) and pirmenol (Reder et al., 1980) , also possess the class IV action (blockade of the voltage-dependent Ca2+ channel).
Several Ca2+ antagonists are reported to suppress the glibenclamide-sensitive K+ currents in oocytes (Sakuta et al., 1992a) . The Ca2' antagonism might change intracellular Ca2+ concentration, inhibit Ca2+-dependent processes and subsequently affect glibenclamide-sensitive K+ currents. The Ca2+ channel blockade by this means, however, is unlikely to be contributing to the suppressive effect of antiarrhythmic drugs on oocyte glibenclamide-sensitive K+ current for the following reasons: (1) the weak Ca2+ antagonists, bepridil and prenylamine, block oocyte glibenclamide-sensitive K+ currents much more potently than strong Ca2+ antagonists, diltiazem and verapamil (Sakuta et al., 1992a) ; (2) typical Ca2+ antagonists, verapamil and diltiazem, require much higher concentrations to block the K+ current than to block Ca2+ channels (Sakuta et al., 1992a) ; (3) both the active Ca2à ntagonist, (-)-verapamil, and the inactive isomer, (+ )-verapamil, equipotently block the K+ current (our unpublished observation); and (4) cibenzoline blocked KRN2391-induced K+ currents in oocytes 19 times more potently than ( ± )-verapamil (cf. Figure 4 and Sakuta et al., 1992a) , whilst the potency of cibenzoline in blocking Ca2" channels is only 1/50 of that of ( ± )-verapamil (Matsuoka et al., 1991) .
Clinical significance of the blockade of glibenclamidesensitive K+ channels by antiarrhythmic drugs Myocardial ATP/glibenclamide-sensitive K+ channels are opened by an ischaemic condition and are thought to play a major role in the ischaemia-induced shortening of action potential duration and consequent generation of ischaemiarelated arrhythmia (Noma, 1983) . Therefore, any drug which can block this type of K+ channel theoretically has the potential to suppress ischaemia-induced arrhythmia (Lynch et al., 1992) . In support of this idea, ATP-sensitive K+ channel blockers glibenclamide and 5-hydroxydecanoate have been reported to suppress experimental ventricular arrhythmia (Kantor et al., 1990; Notsu et al., 1992) . Furthermore, some class I, class II and class IV antiarrhythmic drugs in Vaughan Williams' classification block glibenclamidesensitive K+ channels (Sakuta et al., 1992a ). The present study shows that the class III antiarrhythmic drug, clofilium, and some novel class I antiarrhythmic drugs also block the K+ channels. Thus, it appears that the inhibition of ATP/ glibenclamide-sensitive K+ channels may underlie a part of antiarrhythmic effects of some antiarrhythmic drugs.
Disopyramide, quinidine and ( ± )-cibenzoline are related to rare hypoglycaemic attacks during treatment of arrhythmia (Semel et al., 1983; Phillips et al., 1986; Jeandel et al., 1988) . Disopyramide and quinidine suppress glibenclamidesensitive K+ currents in Xenopus oocytes (Sakuta et al., 1992a) . ( ± )-Cibenzoline also potently blocked the K+ currents (cf. Figures 4 and 6) . Thus, it is conceivable that these drugs might inactivate ATP/glibenclamide-sensitive K+ channels in pancreatic P-cells, and facilitate the secretion of insulin. In support of this, disopyramide, quinine (an optical isomer of quinidine) and imidazoline derivatives have been reported to stimulate the secretion of insulin from islet cells (Henquin et al., 1975; Nakabayashi et al., 1989; Schulz & Hasselblatt, 1989 ).
In conclusion, the antiarrhythmic drugs, ( ± )-cibenzoline and clofilium block the glibenclamide-sensitive K+ channel in Xenopus oocytes at concentrations comparable to their therapeutic plasma concentrations. These drugs are as potent as bepridil which is the strongest blocker of glibenclamidesensitive K+ channels among the antiarrhythmic drugs studied so far.
